Meeting
2024 ASCO Annual Meeting
Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Authors
Yang Xie
Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China
Yang Xie , Qingqing Cai , Haisheng Liu , Ye Guo , Wenrong Huang , Mingzhi Zhang , Yi Xia , Yuhuan Gao , Xilin Chen , Yongjing Tang , Shaoning Yin , Shunzong Yuan , Haiying Li , Yuqin Song
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Clinical Trial Registration Number
NCT06189391
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 7040)
DOI
10.1200/JCO.2024.42.16_suppl.7040
Abstract #
7040
Poster Bd #
23
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 study of AT101, a novel anti-CD19 CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
First Author: Dok Hyun Yoon
Poster
2016 ASCO Annual Meeting
A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (BâNHL).
First Author: Ki Y. Chung
Poster
2014 ASCO Annual Meeting
Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL).
First Author: Anastasios Stathis
Poster
2013 ASCO Annual Meeting
Phase I study of a novel humanized anti-CD20 antibody, BM-ca, in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab.
First Author: Kensei Tobinai